Black subjects tend to retain salt and water, be more sensitive to aldosterone, and have suppression of plasma renin activity. Variants of the renal sodium channel (ENaC, SCNN1B) account for approximately 6% of resistant hypertension (RHT) in Blacks; other candidate genes may be important.
Brief CommuniCation
Low renin hypertension (LRH) is more common in Black Africans and African Americans, 1 and may account for the observation that in the US Black patients have twice the risk of stroke, 2 and are less likely to have their blood pressure (BP) controlled, despite greater awareness of their hypertension, greater likelihood of being treated, and greater likelihood of being treated more intensively. 3 LRH can be divided into 2 distinct phenotypes-low renin and elevated aldosterone (primary aldosteronism) and low renin and low aldosterone (Liddle type syndrome). For example, in South Africa a variant of the beta ENaC (SCNN1B) (R563Q) causes low renin/low aldosterone resistant hypertension (RHT) in 6% of Blacks in urban South Africa and responds to treatment with amiloride, a specific antagonist of the ENaC. 4 Variants of GRK4 have also been implicated in LRH/saltsensitive hypertension; the R65L and A142V alleles were found in most patients tested in a South African study. 5 Primary aldosteronism due to bilateral adrenal hyperplasia is more common in African Americans and variants of aldosterone synthase (CYP11B2) causing familial primary aldosteronism 6, 7 may be more prevalent in the African populations.
Other genes implicated in LRH include those encoding atrial natriuretic peptide (NPPA), NEDD4 ligand (which influences the activity of the ENaC), and uromodulin (UMOD).
Our aim was to search for novel variants of genes associated with salt and water retention in Black African patients with low renin RHT.
High Frequency of Variants of Candidate Genes in Black Africans with Low Renin-Resistant Hypertension

METHODS
Patients
The genetic analysis was part of a larger study that enrolled patients from three sites in sub-Saharan Africa: Nigeria, Kenya, and South Africa. That study aimed to determine if managing RHT according to physiological parameters compared to usual guideline based treatment improved BP control. 8 The number of cases selected for sequencing was determined by funding available. Cases were selected for genotyping were based on inspection of the baseline plasma renin activity (PRA) and plasma aldosterone levels, selecting the most extreme 9 cases for each phenotype: low renin/high aldosterone (primary aldosteronism phenotype) and low renin/low aldosterone (Liddle phenotype).
Measurement of PRA and plasma aldosterone
Blood was drawn at the randomization visit in a fasting condition, while seated for approximately 10 minutes (after BPs were measured). PRA and plasma aldosterone were measured using kits from Diagnostics Biochem (London, Canada). The PRA ELISA kit determined the concentration of angiotensin I in EDTA-plasma using a very specific anti-angiotensin I antibody, a biotinylated angiotensin I tracer and other reagents. PRA was then calculated from the difference in concentration of angiotensin I in samples that were incubated either at 4 °C or 37 °C at slightly acidic pH for approximately 2 hours. Aldosterone concentration was determined directly in the same samples from the DBC ELISA, which also relies on a highly specific antialdosterone antibody. Both kits present good precision with coefficients of variation intra-and interassay smaller than 9% (PRA kit) and 13% (aldosterone kit).
DNA collection and analysis
Blood for DNA was collected at 2 of the sites: Kenya and South Africa. DNA was extracted from whole blood at the University of Cape Town. The DNA was sent to the London Regional Genomics Centre at the Robarts Research Institute in London, Canada, for Sanger sequencing. Only patients with low aldosterone/high aldosterone (primary aldosteronism phenotype) and low renin/low aldosterone (Liddle phenotype) were selected for analysis. The SCNN1B, NPPA, NEDD4L, GRK4, and UMOD genes were sequenced in patients with the Liddle phenotype and CYP11B2 was sequenced in those with the primary aldosteronism phenotype.
Genomic DNA analysis
PCR amplifications were performed using primers covering the coding regions and intron-exon boundaries of the SCNN1B, NPPA, NEDD4L, GRK4, UMOD, and CYP11B2 genes (primers are described in Supplementary Material). PCR amplifications were carried out in 30 µl mixtures containing 32 pmol of each primer, 0.2 mM of each dATP, dCTP, dGTP, and dTTP, 1.5 mM MgCl 2 , 50 mM KCl, 20 mM Tris-HCl (pH 8.4), 1.0 units of Taq Age, years; Sex, M = male, F = female. Abbreviations: Aldo, plasma aldosterone, pg/ml; PRA, plasma renin activity, ng/ml/hr.
platinum DNA polymerase (Invitrogen). Thirty cycles were performed, consisting of denaturation at 95 °C, annealing at 60 °C, and extension at 72 °C for 30 seconds each, followed by a final extension for 7 minutes at 72 °C and cooling to 4 °C. PCR products were purified with CIP/ExoI (New England Biolabs, Pickering, ON, Canada) and sequenced on an ABI 3730 DNA Analyzer (Applied Biosystems, Foster city, CA). DNA sequences were analyzed using Seq Scape v2.6 (Applied Biosystems).
RESULTS
There were 105 patients enrolled in the study, of which 94 completed the study. DNA was collected from 48 patients: 19 from South Africa and 29 from Kenya (see Supplementary Material). Nine patients with low renin and low aldosterone (Liddle phenotype) and 9 patients with low renin and high aldosterone (primary aldosteronism phenotype) were analyzed; the number was dictated by availability of funds. Table 1 shows the baseline characteristics of the patients whose DNA was selected for sequencing. Table 2 shows the nonsynonymous variants (NSVs) detected by sequencing 9 patients with low renin and low aldosterone and 9 patients with low renin and high aldosterone. There were no NSV detected in the NEDD4L gene. However, there were numerous variants detected that did not result in an amino acid change (Supplementary Material). In the CYP11B2 gene, there were 14 NSV detected. Three of these variants have previously been described, one of which was present in all 9 sequenced patients. In 8 of the 11 remaining previously undocumented variants, all 9 patients were found to have the variant.
There was one NSV found in the NPPA gene. This variant was detected in 3 patients. SCNN1B was found to have 3 NSV; 2 of them previously described (G442V and R563Q) and each found in 1 patient, respectively. The previously undocumented variant (R206Q) was found in 2 patients.
The UMOD gene was found to have 3 variants, none previously described. Sequencing of the GRK4 gene revealed 4 variants, of which 3 have previously been described. One of these variants was found in all patients sequenced and another in 8 of the 9 patients sequenced.
The patients that were sequenced originated from a variety of genetic backgrounds. Table 3 shows the origins of the patients and the nucleotide variations that were detected per individual. There was no difference detected in this small number of patients screened, despite different origins.
DISCUSSION
We report a high frequency of genetic variants associated with amino acid mutations in 6 candidate genes implicated in sodium and water retention in Black patients with low reninresistant hypertension. The selection of which genes to screen was based on aldosterone levels. There was high variability in the genes that were selected, in keeping with the genetic diversity that has previously been documented in Africa. 9 The beta subunit of the epithelial sodium channel (SCNN1B) had 3 variants (R206Q, G442V, and R563Q). The R563Q variant has been previously linked to hypertension in South Africa. 4 The G442V variant of the ENaC was previously described in Black people in London 10 but was not associated with hypertension, only lower aldosterone secretion suggesting increased ENaC activity.
Sequencing of the G protein coupled receptor 4 revealed 4 variants with amino acid changes. One of the variants (A116T) has not been previously reported. However, the GRK4 R65L, GRK4 A142V, and GRK4 A486V are 94.4% predictive of salt sensitive hypertension, and the number of GRK4 variants is inversely related to salt excretion. The R65L and A142V GRK4 variants have been linked to BP response to antihypertensive drugs and salt restriction, and ability to excrete sodium. 5, 11 Crucially, GRK4 variants in this study were homozygous for the alternate allele (Table 2 ) and were described in all patients with low renin/low aldosterone despite different geographic locations and genetic backgrounds. Rayner et al. 4 reported that in Black subjects these variants were present in 96% for A142V and 95% for R65L. These preliminary results suggest that GRK4 may possibly be the main driver of low renin/low aldosterone hypertension in Africa. This hypothesis should be investigated in African American patients with RHT. NPPA SCNN1B SCNN1B SCNN1B UMOD UMOD UMOD GRK4  GRK4 GRK4 GRK4   LRLA  V32M  R206Q  G442V  R563Q  D25G  L180V T585I  R65L  A116T A142V V486A   4002 Colored  SA  GA  TT  TC   4021 Colored  SA  CT  TC   4024 Colored  SA  GA  CC   4051 Xhosa  SA  CT  TT  TT  CC   4053 Xhosa  SA  GA  GA  CG  CT  CC   4059 Xhosa  SA  GA  TT  CC   4065  MOZ  SA  GA  AG  CT  CC   3019 Kikuyu Kenya  CG  GT  GA  TT  CC   3031 Kikuyu Kenya  GT  AG  GT  TT  CC   LRHA, CYP11B2  R30Q N82D  P86A  R87G C109R C109Y I112S D147E K152N I248T I339T V386A G435S   4005 Colored  SA  AG  CG  CG  TC  GA  TG  TA  GC  TC  TC   4023 Colored  SA  AG  CG  CG  TC  GA  TG  TA  GC  TC  GA   4031 Colored  SA  GA  AG  CG  CG  TC  GA  TG  TA  GC  TC  CC   4044 Xhosa  SA  GA  AG  CG  CG  TC  GA  TG  TA  GC  TC  TC   4048 Colored  SA  AG  CG  CG  TC  GA  TG  TA  GC  TC   3004 Kalenjin Kenya  AG  CG  CG  TC  GA  TG  TA  GC  TC  TC   3005 Kikuyu Kenya  AG  CG  CG  TC  GA  TG  TA  GC  TC  TC   3034 Kikuyu Kenya  AG  CG  CG  TC  GA  TG  TA  GC  TC  CC   3035 Kalenjin Kenya  AG  CG  CG  TC  GA  TG  TA  GC  TC  CC The NPPA variant has been previously reported to be associated with a lower diastolic BP. The patients in this study all had hypertension. None of the UMOD variants was previously described. The variants in this paper were not compared, so further studies to look for association with renin, aldosterone, and BP are required.
The only gene sequenced for the patients with the primary aldosteronism phenotype was the gene encoding aldosterone synthase: CYP11B2. Multiple amino acid alterations were detected, most of them in the heterozygous form. There were 2 that were found to be homozygous for the variant allele, but neither of these variants has previously been described. Of the 3 variants that have previously been described, all were found to affect steroid production: R87G, V386A, and G435S have been associated with a decreased aldosterone production. [12] [13] [14] However, in this study, the patients with these genotypes had higher aldosterone levels. It is interesting that most of the variants were found in all of the patients, with 1 variant allele.
The most important limitation of this preliminary study was the small numbers of patients studied. However, despite heredity contributing 40-50% to pathogenesis of essential hypertension, 15 genome-wide association studies have only identified 1% of the genetic contribution. 16 This novel approach of enriching the sample by using a phenotypic approach to African patients with low reninresistant hypertension has revealed a surprising number of previously described and novel variants in candidate genes associated with salt and water retention. It informs a basis for conducting a larger and more powerful study to link these variants with low renin-resistant hypertension in Blacks.
In conclusion, this small preliminary study of variants of candidate genes in African patients from diverse backgrounds with low renin-resistant hypertension reveals a surprising number of novel variants and variants previously linked toLRH. Further study is indicated to determine the significance of these findings and the possibility of translating this research into a more physiological approach to treatment of hypertension.
SUPPLEMENTARY MATERIAL
Supplementary data are available at American Journal of Hypertension online.
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